WallStSmart

Merck & Company Inc (MRK)vsUFP Technologies Inc (UFPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 10685% more annual revenue ($65.01B vs $602.80M). MRK leads profitability with a 28.1% profit margin vs 11.3%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

UFPT

Hold

49

out of 100

Grade: D+

Growth: 6.0Profit: 7.0Value: 3.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
UFPTSignificantly Overvalued (-89.1%)

Margin of Safety

-89.1%

Fair Value

$139.28

Current Price

$185.45

$46.17 premium

UndervaluedFair: $139.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

UFPT0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

UFPT3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

Market CapQuality
$1.43B3/10

Smaller company, higher risk/reward

PEG RatioValuation
3.802/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : UFPT

UFPT has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : UFPT

The primary concerns for UFPT are Revenue Growth, Market Cap, PEG Ratio.

Key Dynamics to Monitor

UFPT carries more volatility with a beta of 1.17 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (59/100 vs 49/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

UFP Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.

Want to dig deeper into these stocks?